Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
Recap by typeshit. Full story at Drugs.com.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
The dermatologist says many of her patients take GLP-1s, and calls her own weight loss on Zepbound, which she nicknames vitamin Z, life-changing.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
Loading…